NO971633L - Stabile, vandige <alfa>-interferonopplösningsformuleringer - Google Patents

Stabile, vandige <alfa>-interferonopplösningsformuleringer

Info

Publication number: NO971633L
Authority: NO; Norway
Prior art keywords: alfa; interferon; solution formulations; stable; aqueous
Prior art date: 1994-10-11

Application number

NO971633A

Other languages

English (en)

Other versions

NO320604B1 (no

NO971633D0 (no

Inventor

Pui-Ho C Yuen

Douglas F Kline

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-11

Filing date

1997-04-10

Publication date

1997-04-10

1997-04-10 Application filed by Schering Corp filed Critical Schering Corp

1997-04-10 Publication of NO971633L publication Critical patent/NO971633L/no

1997-04-10 Publication of NO971633D0 publication Critical patent/NO971633D0/no

2005-12-27 Publication of NO320604B1 publication Critical patent/NO320604B1/no

Links

108010050904 Interferons Proteins 0.000 title abstract 3
102000014150 Interferons Human genes 0.000 title abstract 3
229940079322 interferon Drugs 0.000 title abstract 3
238000009472 formulation Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
108010078049 Interferon alpha-2 Proteins 0.000 abstract 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 abstract 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 abstract 1
230000000845 anti-microbial effect Effects 0.000 abstract 1
239000004599 antimicrobial Substances 0.000 abstract 1
239000007864 aqueous solution Substances 0.000 abstract 1
239000002738 chelating agent Substances 0.000 abstract 1
-1 e.g. Proteins 0.000 abstract 1
229940124274 edetate disodium Drugs 0.000 abstract 1
229960003521 interferon alfa-2a Drugs 0.000 abstract 1
229960003507 interferon alfa-2b Drugs 0.000 abstract 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
229920000053 polysorbate 80 Polymers 0.000 abstract 1
229940068968 polysorbate 80 Drugs 0.000 abstract 1
239000003755 preservative agent Substances 0.000 abstract 1
230000002335 preservative effect Effects 0.000 abstract 1
239000011780 sodium chloride Substances 0.000 abstract 1
MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 abstract 1
239000003381 stabilizer Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
239000012929 tonicity agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

NO19971633A 1994-10-11 1997-04-10 Stabile, vandige alfa-interferonopplosningsformuleringer NO320604B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/329,813 US5766582A (en)	1994-10-11	1994-10-11	Stable, aqueous alfa interferon solution formulations
PCT/US1995/012362 WO1996011018A1 (en)	1994-10-11	1995-10-10	Stable, aqueous alfa interferon solution formulations

Publications (3)

Publication Number	Publication Date
NO971633L true NO971633L (no)	1997-04-10
NO971633D0 NO971633D0 (no)	1997-04-10
NO320604B1 NO320604B1 (no)	2005-12-27

Family

ID=23287133

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19971633A NO320604B1 (no)	1994-10-11	1997-04-10	Stabile, vandige alfa-interferonopplosningsformuleringer

Country Status (24)

Country	Link
US (2)	US5766582A (no)
EP (2)	EP0777495B1 (no)
JP (2)	JP3978228B2 (no)
KR (1)	KR100401401B1 (no)
CN (1)	CN1102408C (no)
AT (2)	ATE194774T1 (no)
AU (1)	AU708337B2 (no)
BR (1)	BR9509313A (no)
CA (1)	CA2201749C (no)
CZ (1)	CZ296961B6 (no)
DE (2)	DE69531314T2 (no)
DK (1)	DK0777495T3 (no)
ES (2)	ES2148568T3 (no)
FI (2)	FI116558B (no)
GR (1)	GR3034619T3 (no)
HU (1)	HU225494B1 (no)
NO (1)	NO320604B1 (no)
NZ (1)	NZ294464A (no)
PL (1)	PL183797B1 (no)
PT (1)	PT777495E (no)
RU (1)	RU2157236C2 (no)
SK (1)	SK282949B6 (no)
UA (1)	UA42028C2 (no)
WO (1)	WO1996011018A1 (no)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030190307A1 (en)	1996-12-24	2003-10-09	Biogen, Inc.	Stable liquid interferon formulations
US6180096B1 (en)	1998-03-26	2001-01-30	Schering Corporation	Formulations for protection of peg-interferon alpha conjugates
CA2324467C (en) *	1998-03-26	2002-11-05	Schering Corporation	Formulations for protection of peg-interferon alpha conjugates
DE69901321T2 (de)	1998-05-15	2002-12-12	Schering Corp., Kenilworth	Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind
US6281337B1 (en)	1998-11-12	2001-08-28	Schering Corporation	Methods for conversion of protein isoforms
DK1894944T3 (da)	1998-11-12	2010-10-18	Schering Corp	Fremgangsmåder til omdannelse af interferon-isoformer og produkter deraf
US7402559B2 (en) *	1999-03-24	2008-07-22	Msh Pharma, Incorporated	Composition and method of treatment for urogenital conditions
AR029160A1 (es) *	1999-04-08	2003-06-18	Schering Corp	El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo
US6362162B1 (en)	1999-04-08	2002-03-26	Schering Corporation	CML Therapy
EP1535622B1 (en)	1999-04-08	2008-12-31	Schering Corporation	Melanoma therapy
US6605273B2 (en)	1999-04-08	2003-08-12	Schering Corporation	Renal cell carcinoma treatment
US6923966B2 (en) *	1999-04-08	2005-08-02	Schering Corporation	Melanoma therapy
KR100740794B1 (ko)	1999-04-09	2007-07-20	오르토-맥네일 파마슈티칼, 인코퍼레이티드	에리트로포이에틴의 약제학적 제형
KR100399156B1 (ko) *	1999-11-19	2003-09-26	주식회사 엘지생명과학	α-인터페론의 용액제형
CN1175901C (zh) *	1999-12-06	2004-11-17	天津华立达生物工程有限公司	一种稳定的干扰素水溶液
ATE293159T1 (de) *	1999-12-14	2005-04-15	Thermo Biostar Inc	Stabilisierendes verdünnungsmittel für polypeptide und antigene
JP4536194B2 (ja) *	2000-02-17	2010-09-01	大日本住友製薬株式会社	安定な注射用製剤
CN1245215C (zh)	2001-02-28	2006-03-15	四川省生物工程研究中心	重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
CA2443326A1 (en) *	2001-04-04	2002-10-17	Alza Corporation	Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition
WO2002083165A1 (fr) *	2001-04-10	2002-10-24	Sumitomo Pharmaceuticals Co., Ltd.	Preparations stables destinees a etre injectees
LT4947B (lt)	2001-09-26	2002-08-26	Biotechnologijos Institutas	Interferono alfa farmacinė kompozicija
US20050232899A1 (en) *	2002-05-31	2005-10-20	Aradigm Corporation	Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US6830744B2 (en) *	2002-05-31	2004-12-14	Aradigm Corporation	Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
RU2238758C2 (ru) *	2002-07-24	2004-10-27	Закрытое акционерное общество "Вектор-Медика"	Водный раствор интерферона-альфа-два человека для инъекций
US20040058895A1 (en) *	2002-09-18	2004-03-25	Bone Care International, Inc.	Multi-use vessels for vitamin D formulations
US7148211B2 (en) *	2002-09-18	2006-12-12	Genzyme Corporation	Formulation for lipophilic agents
US20040053895A1 (en) *	2002-09-18	2004-03-18	Bone Care International, Inc.	Multi-use vessels for vitamin D formulations
US20040175359A1 (en) *	2002-11-12	2004-09-09	Desjarlais John Rudolph	Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7585647B2 (en)	2003-08-28	2009-09-08	Guangwen Wei	Nucleic acid encoding recombinant interferon
BRPI0507169A (pt) *	2004-02-02	2007-06-26	Ambrx Inc	polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
CN1724567B (zh) *	2004-07-22	2010-08-18	北京三元基因工程有限公司	一种稳定的重组人干扰素α1b水溶液
EP1796647B1 (en)	2004-08-12	2010-08-11	Schering Corporation	Stable pegylated interferon formulation
US20060204474A1 (en) *	2005-02-25	2006-09-14	Coroneo Minas T	Treatment of epithelial layer lesions
ES2302402B1 (es)	2005-06-16	2009-05-08	Proyecto De Biomedicina Cima, S.L.	Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
RU2294372C1 (ru) *	2005-06-16	2007-02-27	ООО "Цитокин"	СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2b И ИНТЕРФЕРОНСОДЕРЖАЩИЙ ПРЕПАРАТ (ВАРИАНТЫ)
CU23432B6 (es)	2005-11-02	2009-10-16	Ct Ingenieria Genetica Biotech	Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
US8679472B1 (en)	2006-10-05	2014-03-25	Merck, Sharp & Dohme Corp.	Crystal of human interferon alpha 2B in complex with zinc
CN101675071B (zh)	2007-05-02	2014-06-18	Ambrx公司	经修饰干扰素β多肽和其用途
RU2010120674A (ru) *	2007-10-22	2011-11-27	Шеринг Корпорейшн (US)	Полностью человеческие анти-vegf-антитела и способы их применения
WO2009120991A2 (en) *	2008-03-27	2009-10-01	Medtronic, Inc.	Pharmacokinetic and pharmacodynamic tools to define patient specific therapeutic regimens
EP2305309A2 (en)	2008-06-13	2011-04-06	Proyecto de Biomedicina Cima, S.L.	Conjugates for the administration of biologically active compounds
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
PH12011502708B1 (en)	2009-07-06	2017-11-10	Sanofi Aventis Deutschland	Insulin preparations containing methionine
SG10201500871TA (en)	2009-11-13	2015-04-29	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
KR101303388B1 (ko) *	2010-10-26	2013-09-03	한미사이언스 주식회사	지속형 인터페론 알파 결합체의 액상 제제
BR112013032188A2 (pt)	2011-06-23	2016-12-20	Digna Biotech Sl	composição, produto e método para tratar pacientes com hepatite c crônica
CA2888442A1 (en)	2012-10-26	2014-05-01	Lupin Limited	Stable pharmaceutical composition of peginterferon alpha-2b
EP3517122A1 (en)	2013-04-03	2019-07-31	Sanofi	Treatment of diabetes mellitus by long-acting formulations of insulins
US9388239B2 (en)	2014-05-01	2016-07-12	Consejo Nacional De Investigation Cientifica	Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
ES2524516B1 (es) *	2014-05-29	2015-03-31	Grifols Worldwide Operations Limited	Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
WO2016046101A1 (en) *	2014-09-23	2016-03-31	F. Hoffmann-La Roche Ag	Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon
CN107206058A (zh)	2014-12-12	2017-09-26	赛诺菲-安万特德国有限公司	甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
AR105044A1 (es) *	2015-06-18	2017-08-30	Sage Therapeutics Inc	Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
RU2623050C2 (ru) *	2015-12-03	2017-06-21	Виталий Эдуардович Боровиков	Раствор хондроитина сульфата для внутримышечного введения и способ его получения
KR200492470Y1 (ko)	2020-03-26	2020-10-21	사공탁	빌라 주택용 쓰레기 수거함
RU2768656C1 (ru) *	2021-09-10	2022-03-24	Илья Александрович Марков	Противовирусное средство в жидкой форме и способ его приготовления
CN113797318B (zh) *	2021-10-26	2023-06-30	深圳科兴药业有限公司	一种干扰素组合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0082481B2 (en) *	1981-12-23	1990-09-12	Schering Corporation	Stabilised alpha-interferon formulations and their preparation
JPS59176216A (ja) *	1983-03-28	1984-10-05	Sumitomo Chem Co Ltd	有用なインタ−フエロン製剤
US4680175A (en) *	1984-02-07	1987-07-14	Interferon Sciences, Inc.	Interferon administration vehicles
JPS60243028A (ja) *	1984-04-28	1985-12-03	Kyowa Hakko Kogyo Co Ltd	インタ−フエロンの可溶化方法
US4606917A (en) *	1984-10-03	1986-08-19	Syntex (U.S.A) Inc.	Synergistic antiviral composition
US4857316A (en) *	1984-10-03	1989-08-15	Syntex (U.S.A.) Inc.	Synergistic antiviral composition
JPS61277633A (ja) *	1985-05-31	1986-12-08	Toray Ind Inc	インタ−フエロン組成物
US4847079A (en) *	1985-07-29	1989-07-11	Schering Corporation	Biologically stable interferon compositions comprising thimerosal
EP0284249A1 (en) *	1987-03-13	1988-09-28	Interferon Sciences, Inc.	Lyophilized lymphokine composition
US4950652A (en) *	1987-03-23	1990-08-21	Hem Research, Inc.	dsRNAs for combination therapy in the treatment of viral diseases
US5266310A (en) *	1987-09-17	1993-11-30	Boehringer Ingelheim International Gmbh	Stabilization of therapeutically active proteins in pharmaceutical preparations
IL88233A (en) *	1987-11-03	1993-08-18	Genentech Inc	Gamma interferon formulation
DE4126983A1 (de) *	1991-08-15	1993-02-18	Boehringer Mannheim Gmbh	Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JP3292894B2 (ja) *	1993-05-12	2002-06-17	日本電信電話株式会社	集積化受光回路

1994
- 1994-10-11 US US08/329,813 patent/US5766582A/en not_active Expired - Lifetime
1995
- 1995-10-10 SK SK439-97A patent/SK282949B6/sk not_active IP Right Cessation
- 1995-10-10 WO PCT/US1995/012362 patent/WO1996011018A1/en not_active Ceased
- 1995-10-10 UA UA97052124A patent/UA42028C2/uk unknown
- 1995-10-10 DK DK95935151T patent/DK0777495T3/da active
- 1995-10-10 CZ CZ0110497A patent/CZ296961B6/cs not_active IP Right Cessation
- 1995-10-10 DE DE69531314T patent/DE69531314T2/de not_active Expired - Lifetime
- 1995-10-10 BR BR9509313A patent/BR9509313A/pt not_active IP Right Cessation
- 1995-10-10 JP JP51260696A patent/JP3978228B2/ja not_active Expired - Lifetime
- 1995-10-10 ES ES95935151T patent/ES2148568T3/es not_active Expired - Lifetime
- 1995-10-10 PT PT95935151T patent/PT777495E/pt unknown
- 1995-10-10 EP EP95935151A patent/EP0777495B1/en not_active Expired - Lifetime
- 1995-10-10 CA CA002201749A patent/CA2201749C/en not_active Expired - Lifetime
- 1995-10-10 AU AU37279/95A patent/AU708337B2/en not_active Expired
- 1995-10-10 NZ NZ294464A patent/NZ294464A/xx not_active IP Right Cessation
- 1995-10-10 AT AT95935151T patent/ATE194774T1/de active
- 1995-10-10 PL PL95319603A patent/PL183797B1/pl unknown
- 1995-10-10 DE DE69518084T patent/DE69518084T2/de not_active Expired - Lifetime
- 1995-10-10 ES ES99119434T patent/ES2198830T3/es not_active Expired - Lifetime
- 1995-10-10 RU RU97107611/14A patent/RU2157236C2/ru active
- 1995-10-10 KR KR1019970702346A patent/KR100401401B1/ko not_active Expired - Lifetime
- 1995-10-10 HU HU9702262A patent/HU225494B1/hu unknown
- 1995-10-10 CN CN95195600A patent/CN1102408C/zh not_active Expired - Lifetime
- 1995-10-10 EP EP99119434A patent/EP0970703B1/en not_active Expired - Lifetime
- 1995-10-10 AT AT99119434T patent/ATE245033T1/de not_active IP Right Cessation
1997
- 1997-04-10 FI FI971486A patent/FI116558B/fi not_active IP Right Cessation
- 1997-04-10 NO NO19971633A patent/NO320604B1/no not_active IP Right Cessation
1998
- 1998-06-12 US US09/096,708 patent/US5935566A/en not_active Expired - Lifetime
2000
- 2000-10-13 GR GR20000402304T patent/GR3034619T3/el unknown
2005
- 2005-10-19 FI FI20055562A patent/FI117377B/fi not_active IP Right Cessation
2006
- 2006-04-20 JP JP2006117296A patent/JP2006193536A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP0777495B1 (en)	2000-07-19
DE69518084T2 (de)	2001-03-22
CN1160355A (zh)	1997-09-24
GR3034619T3 (en)	2001-01-31
SK282949B6 (sk)	2003-01-09
ES2148568T3 (es)	2000-10-16
AU3727995A (en)	1996-05-02
RU2157236C2 (ru)	2000-10-10
ATE194774T1 (de)	2000-08-15
NO320604B1 (no)	2005-12-27
HK1008813A1 (en)	1999-05-21
CN1102408C (zh)	2003-03-05
FI117377B (fi)	2006-09-29
CA2201749C (en)	1999-06-15
EP0970703B1 (en)	2003-07-16
DK0777495T3 (da)	2000-11-06
UA42028C2 (uk)	2001-10-15
FI971486L (fi)	1997-04-10
BR9509313A (pt)	1998-01-27
AU708337B2 (en)	1999-08-05
DE69531314D1 (de)	2003-08-21
ATE245033T1 (de)	2003-08-15
PT777495E (pt)	2000-12-29
HU225494B1 (en)	2007-01-29
DE69518084D1 (de)	2000-08-24
JP3978228B2 (ja)	2007-09-19
US5935566A (en)	1999-08-10
MX9702578A (es)	1997-07-31
FI116558B (fi)	2005-12-30
NZ294464A (en)	1999-03-29
NO971633D0 (no)	1997-04-10
EP0777495A1 (en)	1997-06-11
CZ110497A3 (en)	1997-09-17
CA2201749A1 (en)	1996-04-18
ES2198830T3 (es)	2004-02-01
FI20055562L (fi)	2005-10-19
JPH10506912A (ja)	1998-07-07
SK43997A3 (en)	1997-10-08
PL319603A1 (en)	1997-08-18
EP0970703A1 (en)	2000-01-12
PL183797B1 (pl)	2002-07-31
KR100401401B1 (ko)	2004-02-18
DE69531314T2 (de)	2004-05-13
KR970706017A (ko)	1997-11-03
WO1996011018A1 (en)	1996-04-18
CZ296961B6 (cs)	2006-08-16
FI971486A0 (fi)	1997-04-10
US5766582A (en)	1998-06-16
HUT77287A (hu)	1998-03-30
JP2006193536A (ja)	2006-07-27

Legal Events

Date

Code

Title

Description

2012-09-24

CHAD

Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

2015-10-26

MK1K

Patent expired

Publication	Publication Date	Title
NO971633D0 (no)	1997-04-10	Stabile, vandige <alfa>-interferonopplösningsformuleringer
NO308848B1 (no)	2000-11-06	Kromanforbindelse og farmasøytisk preparat som inneholder den
EP0838221A4 (en)	2003-01-15	LYOPHILIZED HGF PREPARATIONS
FR2773486B1 (fr)	2001-04-06	Composition de soin des levres contenant de l'acide acexamique, ses utilisations
ATE273033T1 (de)	2004-08-15	Stabilisierte ophthalmische wasserstoffperoxidlösung
DK0490549T3 (da)	1995-08-21	Stabilisering af calcitonin-holdige farmaceutiske præparater
CO4560591A1 (es)	1998-02-10	Sistema corrector de tinta
IT1247945B (it)	1995-01-05	Agente avente attivita' batteriostatica e battericida
NZ505821A (en)	2002-09-27	Pharmaceutical compositions of uridine triphosphate
ATE88697T1 (de)	1993-05-15	E-isomere von n alpha-(2-cyan-2-alkoximinoacetyl)-amino-s\|urederivaten und -peptiden.
DK0381617T3 (da)	1996-06-10	Desinfektions- og rensemiddel til kontaktlinser
DE60226836D1 (de)	2008-07-10	Stabile Elektrolytlösungen enthaltend Taurolidin
ES2022448B3 (es)	1991-12-01	Composicion desinfectante para lentes de contacto blandas, que contienen una disolucion de peroxido de hidrogeno estabilizada.
NO20012817D0 (no)	2001-06-07	Phenethyl-5-bromopyridylthiourea (PBT) og dihydroalkoxybenzyloxopyrimidine (DABO) derivater som utöverspermicidal aktivitet
FI943705A0 (fi)	1994-08-10	Farmaseuttiset koostumukset
DE69825977D1 (de)	2004-10-07	Antivirale mittel
ES2154659T3 (es)	2001-04-16	Soluciones acuosas de isotiazolin-3-onas estables al almacenamiento.
DK443988A (da)	1989-02-11	Injektionspraeparat indeholdende modificeret tpa
FR2718923B1 (fr)	1996-05-31	Composition désinfectante en solution aqueuse renfermant de l'orthophtalaldéhyde.
DK0506563T3 (da)	1995-05-15	Alginsyresuspension
ES2190267T3 (es)	2003-07-16	Recipiente de plastico que contiene formulaciones de farmacos estabilizadas.
SE9502927D0 (sv)	1995-08-24	Solution containing IGF-I
RU2006123317A (ru)	2008-01-20	Состав раствора эритропоэтина
IT1247752B (it)	1994-12-30	Composizioni farmaceutiche aventi come principio attivo calcitonina da somministrarsi per via intranasale.
TH19245A (th)	1996-06-21	วิธีป้องกันการสลายของโปรตีนซี